Cardiff Oncology reports Q3 2026 results, preps Phase 3 onvansertib trial for Q1 2027
Median PFS has not been reached in the 30 mg onvansertib arm versus about 11 months for standard of care, as the company prepares a registrational Phase 3 study.
SEC filing (7)